Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape.#This article provides an overview of the latest advances in BsAbs immun...
Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma Targeted Oncology Staff December 23rd 2024 In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease....
Experts discuss the impact of advances in the treatment of multiple myeloma on patient care. This video discusses the evolving landscape of bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM). The specialists are Ryan Haumschild, PharmD, MS, MBA; hematologist Matthew Pianko, ...
Check point signaling is an important immunosuppressive component of the myeloma microenvironment [128]. Induction of check point expression on B cells due to the effective T cell activation conferred by BsAb is a well-studied phenomenon [129,130]. Due to the release of the pro-inflammatory cytok...
针对这个靶点,Car-T、ADC、Bispecific antibody是三大支柱。作为这个新靶点新药开发的领跑者, GSK、BMS、Johnson &Johnson三家公司 在本届ASCO 各自带着自己的拳头产品前来赶场。为什么说是赶场而不是高调亮相?因为Multiple myeloma的专属舞台是ASH...
the surface of plasma cells. The other prong of the antibody binds CD3 on T cells and activates T cells, basically creates an immune synapse between the T cell and the myeloma cell, and engages that T cell to destroy the myeloma cell—the blinatumomab, if you will, of multiple myeloma. ...
Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC Ilson Examines Ch...
Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x ...
In October 2022, teclistimab-cqyv (Tecvayli), another bispecific antibody therapy targeting BCMA and CD3, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat myeloma that persisted after four or more lines of prior therapy. ...
Bispecific T-cell antibodiesCD38BCMAPurpose of Review The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody...